Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) and Iron Sucrose in Subjects With Iron Deficiency Anemia (FERWON-IDA)
Sponsor: Pharmacosmos A/S
A PHASE3 clinical study on Iron Deficiency Anaemia and Iron Deficiency Anemia, this trial is completed. The trial is conducted by Pharmacosmos A/S and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2020 — Nov 2020 [monthly]
Completed PHASE3
-
Apr 2019 — Apr 2020 [monthly]
Completed PHASE3
-
Oct 2018 — Apr 2019 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmacosmos A/S
For direct contact, visit the study record on ClinicalTrials.gov .